ES2913497T3 - Variantes de GM-CSF y métodos de uso - Google Patents

Variantes de GM-CSF y métodos de uso

Info

Publication number
ES2913497T3
ES2913497T3 ES17810920T ES17810920T ES2913497T3 ES 2913497 T3 ES2913497 T3 ES 2913497T3 ES 17810920 T ES17810920 T ES 17810920T ES 17810920 T ES17810920 T ES 17810920T ES 2913497 T3 ES2913497 T3 ES 2913497T3
Authority
ES
Spain
Prior art keywords
csf
variant
colitis
ibd
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17810920T
Other languages
English (en)
Spanish (es)
Inventor
Thomas Rutkoski
Alexey Teplyakov
Nicole Wunderler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Application granted granted Critical
Publication of ES2913497T3 publication Critical patent/ES2913497T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
ES17810920T 2016-06-08 2017-06-07 Variantes de GM-CSF y métodos de uso Active ES2913497T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662347342P 2016-06-08 2016-06-08
US201662374068P 2016-08-12 2016-08-12
US201662423857P 2016-11-18 2016-11-18
PCT/US2017/036316 WO2017214249A2 (en) 2016-06-08 2017-06-07 Gm-csf variants and methods of use

Publications (1)

Publication Number Publication Date
ES2913497T3 true ES2913497T3 (es) 2022-06-02

Family

ID=60573606

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17810920T Active ES2913497T3 (es) 2016-06-08 2017-06-07 Variantes de GM-CSF y métodos de uso

Country Status (15)

Country Link
US (2) US10562948B2 (zh)
EP (1) EP3468603B1 (zh)
JP (2) JP7050007B2 (zh)
KR (1) KR20190017868A (zh)
CN (1) CN109328071B (zh)
AU (1) AU2017277438A1 (zh)
CA (1) CA3026803A1 (zh)
DK (1) DK3468603T3 (zh)
ES (1) ES2913497T3 (zh)
IL (1) IL263379A (zh)
MA (1) MA45257A (zh)
PT (1) PT3468603T (zh)
TW (1) TW201808987A (zh)
UY (1) UY37281A (zh)
WO (1) WO2017214249A2 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202214445D0 (en) * 2022-09-30 2022-11-16 Imp College Innovations Ltd Gene therapy

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US20080076706A1 (en) * 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
EP1881005B1 (en) * 1997-07-14 2013-04-03 Bolder Biotechnology, Inc. Derivatives of G-CSF and related proteins
US7153943B2 (en) * 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
ATE462004T1 (de) 1997-09-16 2010-04-15 Centocor Inc Methoden zur kompletten chemischen synthese und zusammensetzung von genen und genomen
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR20030082962A (ko) 2001-03-08 2003-10-23 메르크 파텐트 게엠베하 감소된 면역원성을 갖는 개질된과립구대식세포집락자극인자(ｇｍ-ｃｓｆ)
CN1233823C (zh) * 2001-04-13 2005-12-28 上海华康生物技术有限公司 抗原致敏的人gm－csf基因修饰的人树突状细胞、其制法和用途
AU2003263552A1 (en) * 2002-09-09 2004-03-29 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
GB0317999D0 (en) * 2003-07-31 2003-09-03 Univ Liege Improvements in or relating to drug delivery systems
MX2007000568A (es) * 2004-07-16 2007-03-30 Nektar Therapeutics Al Corp Conjugados de una fraccion gm-csf y un polimero.
WO2007009208A1 (en) 2005-06-02 2007-01-25 Cangene Corporation Poly(ethylene glocol) modified human gm-csf with increased biological activity
CN100579988C (zh) * 2007-04-02 2010-01-13 中国疾病预防控制中心病毒病预防控制所 白喉毒素与gm-csf突变体的融合蛋白及其编码基因与应用
PT2506871T (pt) 2009-11-30 2016-11-07 Janssen Biotech Inc Mutantes de fc de anticorpos com funções efetoras inutilizadas
SI2948559T1 (en) * 2013-01-25 2018-08-31 Janssen Biotech, Inc. KV1.3 antagonists and application procedures

Also Published As

Publication number Publication date
EP3468603B1 (en) 2022-04-13
UY37281A (es) 2018-01-02
US10562948B2 (en) 2020-02-18
EP3468603A4 (en) 2020-01-22
CN109328071A (zh) 2019-02-12
JP2022043051A (ja) 2022-03-15
JP7050007B2 (ja) 2022-04-07
EP3468603A2 (en) 2019-04-17
TW201808987A (zh) 2018-03-16
WO2017214249A3 (en) 2018-01-18
US20170355742A1 (en) 2017-12-14
US11208450B2 (en) 2021-12-28
MA45257A (fr) 2019-04-17
KR20190017868A (ko) 2019-02-20
US20200148736A1 (en) 2020-05-14
CA3026803A1 (en) 2017-12-14
CN109328071B (zh) 2021-07-20
PT3468603T (pt) 2022-07-21
JP2019524062A (ja) 2019-09-05
AU2017277438A1 (en) 2018-12-13
IL263379A (en) 2018-12-31
DK3468603T3 (da) 2022-05-30
WO2017214249A2 (en) 2017-12-14

Similar Documents

Publication Publication Date Title
JP6262722B2 (ja) 関節リウマチの予防用または治療用組成物
JP2020171316A (ja) アルファ−１抗トリプシン融合分子のための組成物、方法および使用
ES2577532T3 (es) Nueva composición y métodos para el tratamiento de enfermedades relacionadas con el sistema inmune
JP6938565B2 (ja) Ｕｔｉ融合タンパク質
EP3737402B1 (en) Modified protein
JP2020531030A (ja) Ｇｌｐ−２融合ポリペプチドならびに消化管の状態を処置および予防するための使用
ES2269509T3 (es) Gen expresado altamente en el tejido cartilaginoso.
ES2913497T3 (es) Variantes de GM-CSF y métodos de uso
JP2018529729A (ja) 胆汁酸障害の処置
JP2013253079A (ja) 生物学的に活性なヒト尿中トリプシンインヒビターのＦｃ融合タンパク質並びにその調製および使用
WO2005095443A1 (ja) ペプチド改変を利用したドラッグデリバリーシステム
TWI835772B (zh) Il-22fc融合蛋白及使用方法
TWI835773B (zh) 組合物及使用方法
US7361486B2 (en) Polynucleotide, vector, host cell and method for producing human hepatoma-derived growth factor 5 polypeptide
AU2022313151A1 (en) Human fibronectin type iii protein scaffolds
BR122023015739B1 (pt) Proteínas de fusão uti, seus usos,composição farmacêutica compreendendo a referida proteína e método de produção de uma proteína de fusão uti